The company highlighted the first results from the P-II study evaluating TAR-200 monotx. and cetrelimab monotx. in 200 patients with Bacillus Calmette-Guérin (BCG)-unresponsive HR-NMIBC who are ineligible for or decline, radical cystectomy
The results showed that patients treated with TAR-200 & cetrelimab monotx. achieved the 1EPs of a CR (72.7% & 38.1%) & the results were presented at AUA 2023. Additionally, initial results showed low rates of grade ≥3 AEs and limited no. of treatment discontinuations due to AEs were reported
TAR-200, a novel investigational intravesical drug delivery system & cetrelimab is an investigational anti-PD-1 mAb. TAR-200 is being studied in (SunRISe-2) & (SunRISe-4) trials for muscle-invasive bladder cancer
Ref: PR Newswire | Image: Janssen
Related News:- Janssen Reports P-I Study (CHRYSALIS) Results of Rybrevant (amivantamab-vmjw) for Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
